OrthoClinical Diagnostics News
News on OrthoClinical Diagnostics (Ticker: JNJ) continually updated from thousands of sources around the net.
2 hrs ago | Barron's
Johnson & Johnson was giving up some of Tuesday's gains , although analysts were largely upbeat about the company's better-than-expected first-quarter earnings report, as evidenced by a flurry of target price increases.
Trending on the Topix Network
6 hrs ago | Canadian Business Magazine
Several smartphone apps are available to help patients take their medications as prescribed.
11 hrs ago | Seeking Alpha
Background : Johnson & Johnson may be the bluest of all U.S. blue chip stocks now.
Shares of Twitter closed up 11.38% on Tuesday with about 24.2 million shares traded.
Johnson & Johnson, the world's biggest maker of health-care products, beat expectations and raised its 2014 forecast by focusing on new drugs and reducing its reliance on medical devices.
Stocks gave up early gains and were trading lower in late morning trading Tuesday.
Wall Street advanced overnight, spearheaded by gains in shares of Coca-Cola and Johnson & Johnson after both companies reported quarterly results that surpassed expectations, bolstering confidence about the outlook.
The Dow Jones Industrial Average was earlier trying to extend Monday's positive momentum, and helping toward this goal were Dow components The Coca-Cola Company and Johnson & Johnson , which remain in the black on well-received earnings reports.
Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.
In 2012, the star performer among sectors was the financial sector. In 2013, it was consumer discretionary stocks.
Johnson & Johnson said on Friday it was ending its efforts to bring to market a rival drug to Allergan Inc's popular Botox anti-wrinkle treatment.
Alan Auerbach, the former CEO of Cougar Biotechnology -- the company that developed Johnson & Johnson 's widely successful Zytiga prostate cancer drug -- hopes he has another blockbuster potential drug on his hands at Puma Biotechnology Xeloda head to head against GlaxoSmithKline 's Tykerb and Xeloda.
William C. Geary III, Lisa Adams, and Christina Sperry have joined as members of Mintz Levin's Boston office, the firm said in a Thursday press release .